CRIS Current Research Information System

BRIOLI, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.283
EU - Europa 1.284
AS - Asia 600
AF - Africa 111
SA - Sud America 2
OC - Oceania 1
Totale 4.281
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.274
GB - Regno Unito 420
CN - Cina 252
SE - Svezia 202
DE - Germania 168
IT - Italia 150
VN - Vietnam 120
SG - Singapore 117
IN - India 89
FR - Francia 67
IE - Irlanda 62
RU - Federazione Russa 57
UA - Ucraina 46
ZA - Sudafrica 38
EE - Estonia 36
CI - Costa d'Avorio 32
TG - Togo 31
CH - Svizzera 23
BE - Belgio 14
BG - Bulgaria 13
FI - Finlandia 12
CA - Canada 9
IR - Iran 8
NG - Nigeria 8
JO - Giordania 5
JP - Giappone 4
LB - Libano 4
ES - Italia 2
GR - Grecia 2
NL - Olanda 2
PL - Polonia 2
SC - Seychelles 2
AT - Austria 1
AU - Australia 1
BR - Brasile 1
CL - Cile 1
CZ - Repubblica Ceca 1
HU - Ungheria 1
KR - Corea 1
LT - Lituania 1
LV - Lettonia 1
PT - Portogallo 1
Totale 4.281
Salva come PNG Salva come JPEG
Città #
Southend 384
Fairfield 333
Chandler 230
Ashburn 215
Woodbridge 184
Seattle 153
Wilmington 139
Cambridge 135
Houston 125
Ann Arbor 114
Singapore 100
Princeton 90
Dublin 61
Dong Ket 52
Nanjing 45
Westminster 39
Padova 38
Bologna 35
Jinan 33
Abidjan 32
Lomé 31
New York 31
Santa Clara 24
Shenyang 24
Beijing 23
Bremen 23
Saint Petersburg 21
Jacksonville 20
Nanchang 17
Berlin 16
Changsha 15
Hebei 15
Brussels 14
San Diego 14
Turin 14
Redwood City 13
Sofia 13
Bern 12
Helsinki 12
Dearborn 11
Tianjin 11
Falls Church 8
Hangzhou 8
Jiaxing 8
Abeokuta 7
Boardman 7
Mülheim 7
Paris 7
Washington 7
Medford 6
Milan 6
Norwalk 6
Toronto 6
Zhengzhou 6
Amman 5
Haikou 5
Hyderabad 5
Lausanne 5
Ningbo 5
Argelato 4
Des Moines 4
Fuzhou 4
Guangzhou 4
Los Angeles 4
Modena 4
Monmouth Junction 4
Redmond 4
Romainville 4
Taiyuan 4
Tokyo 4
Florence 3
Geneva 3
Kuban 3
Kunming 3
London 3
Olalla 3
Pune 3
Zanjan 3
Andover 2
Arezzo 2
Boydton 2
Dongguan 2
Faenza 2
Fornovo di Taro 2
Frankfurt am Main 2
Groningen 2
Hockenheim 2
Kilburn 2
Lanzhou 2
Leawood 2
Mahé 2
Moscow 2
Naples 2
Shenzhen 2
Taizhou 2
Tappahannock 2
West Jordan 2
Winnipeg 2
Zurich 2
Acton 1
Totale 3.136
Salva come PNG Salva come JPEG
Nome #
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 189
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 178
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 165
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 150
Thalidomide maintenance in multiple myeloma: certainties and controversies. 143
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 142
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 135
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 133
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 123
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 121
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 120
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 117
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 117
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 115
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 112
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 109
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 107
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 107
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. 106
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 106
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 104
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 104
Role of consolidation therapy in transplant eligible multiple myeloma patients. 102
The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma. 98
Patient with ataxia telangiectasia who developed acute myeloid leukemia. 95
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma 94
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. 93
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 93
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 91
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 88
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. 88
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 88
The impact of response on bone-directed therapy in patients with multiple myeloma. 85
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. 84
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 77
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. 76
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. 75
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. 73
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. 55
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients 40
Proteasome inhibitors: Bortezomib in multiple myeloma 32
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 20
Pomalidomide combinations are a safe and effective option after daratumumab failure 17
Totale 4.367
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.909
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.909
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.136 0 0 5 80 138 135 173 172 196 102 48 87
2020/2021571 125 46 17 17 16 19 13 36 69 26 18 169
2021/2022750 50 32 45 59 77 40 16 56 26 65 126 158
2022/2023889 87 136 36 148 58 83 23 43 146 25 60 44
2023/2024267 18 34 15 28 30 80 18 4 2 22 4 12
2024/2025189 36 152 1 0 0 0 0 0 0 0 0 0
Totale 4.367